Orphazyme gets investor backing for fundraising round

Danish biotech company Orphazyme has received support for its plan to raise new funds after setbacks in 2021.

Photo: Orphazyme/PR

Biotech company Orphazyme needs more funds to get its drug candidate arimoclomol to market.

At a recent extraordinary general meeting it was therefore decided that the firm would issue shares worth between DKK 20m and DKK 40m (USD 3.1m–6.1m), Orphazyme writes in a stock exchange notification.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs